← Browse by Condition
Medical Condition

hematological malignancies

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 2, Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for hematological malignancies sourced from ClinicalTrials.gov. Each listing includes the NCT identifier, current recruitment status, phase, primary endpoints, sponsor, estimated enrollment, and participating countries — updated daily as new studies open and status changes.

  • Recruiting trials currently enrolling participants, with eligibility criteria and age requirements
  • Phase 1–4 studies from early safety trials to post-marketing surveillance
  • NIH, pharmaceutical sponsor, and academic medical center studies worldwide
  • AI-powered plain-language summary available for every trial listing

Frequently Asked Questions — hematological malignancies Clinical Trials

How many clinical trials are currently recruiting for hematological malignancies?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for hematological malignancies, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for hematological malignancies?
hematological malignancies research spans Phase 1 (1 trial), Phase 2 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a hematological malignancies clinical trial?
Eligibility criteria for hematological malignancies trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
1
Phase 2
2
Top Sponsors
Janssen Research & Development, LLC 1 trial
Smart Immune SAS 1 trial
First Affiliated Hospital of Zhejiang University 1 trial

Recruiting Clinical Trials

NCT04634552 Phase 2
Recruiting

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

Enrollment
510 pts
Location
United States, Belgi...
Sponsor
Janssen Research & Development...
View Trial →
NCT04959903 Phase 1, Phase 2
Recruiting

Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT

Enrollment
36 pts
Location
United States
Sponsor
Smart Immune SAS
View Trial →
NCT07122674
Recruiting

18F-Pentixafor PET in Hematologic Malignancies

Enrollment
100 pts
Location
China
Sponsor
First Affiliated Hospital of Z...
View Trial →
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology